COPD clinical trials in Georgia
12 studies for COPD are looking for participants at sites in Georgia.
Cities in Georgia
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
RecruitingPhase 4
Ages 40 to 85 · All sexes · Updated Sep 22, 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07190222A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- and 1 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Aug 26, 2026 · NCT06283966To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
RecruitingPhase 2
Ages 40 to 85 · All sexes · Updated Aug 7, 2026 · NCT07684820eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
RecruitingPhase 2
Ages 35 to 89 · All sexes · Updated May 15, 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- and 1 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Apr 9, 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
RecruitingObservational study
Ages 50 and older · All sexes · Updated Aug 5, 2025 · NCT06122077From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.